Department of Pathology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Expert Rev Mol Diagn. 2013 Sep;13(7):749-62. doi: 10.1586/14737159.2013.835573.
The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.
酪氨酸激酶抑制剂 (TKIs) 用于治疗慢性髓性白血病 (CML)，代表了现代靶向癌症治疗的范例。重要的是，使用 BCR-ABL 实时定量逆转录聚合酶链反应 (RQ-PCR) 进行分子监测，以评估治疗效果并定量检测微小残留疾病，是长期管理这种慢性疾病的实际治疗决策的主要决定因素。本文概述了 CML 以及 TKI 用于靶向 CML 治疗，重点介绍了基于 PCR 的分子监测的作用、应用和未来方面。
